SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
171.03
+7.62 (+4.66%)
At close: 4:00PM EDT

171.03 0.00 (0.00%)
After hours: 4:50PM EDT

Stock chart is not supported by your current browser
Previous Close163.41
Open163.30
Bid163.53 x 900
Ask176.13 x 800
Day's Range163.30 - 171.26
52 Week Range79.88 - 177.05
Volume418,022
Avg. Volume510,019
Market Cap8.748B
Beta (3Y Monthly)3.20
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Ligand Grants Preclinical Candidate Rights to UK-based Firm
    Zacksyesterday

    Ligand Grants Preclinical Candidate Rights to UK-based Firm

    Ligand (LGND) grants exclusive worldwide rights to a pre-clinical cancer candidate discovered using Vernalis Design platform to Cumulus Oncology.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of SAGE earnings conference call or presentation 2-May-19 12:00pm GMT

    Q1 2019 SAGE Therapeutics Inc Earnings Call

  • American City Business Journals12 days ago

    New England Venture Capital Association names 2019 NEVY Awards winners

    The final winners are selected by the NEVYs Technology, Healthcare and Life Sciences Academies among a pool of nominees revealed in March. This year's seventh annual NEVYs marked the first time the Healthcare category had a dedicated Academy distinct from Life Sciences.

  • Small-Cap Stocks to Watch in May
    Motley Fool13 days ago

    Small-Cap Stocks to Watch in May

    These two companies are set to announce important business updates this month.

  • Markit14 days ago

    See what the IHS Markit Score report has to say about SAGE Therapeutics Inc.

    SAGE Therapeutics Inc NASDAQ NMS:SAGEView full report here! Summary * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NegativeShort interest is moderately high for SAGE with between 10 and 15% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.47 billion over the last one-month into ETFs that hold SAGE are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community
    CNBC24 days ago

    Sage Therapeutics' Zulresso is a big win for postpartum depression sufferers — and maybe even the entire mental health community

    In June, Zulresso — the first and only medicine approved by the Food and Drug Administration to specifically treat postpartum depression — will hit the market. Sage Therapeutics, the maker of the drug, now hopes to win the fight against another major issue: The public's misconception about mental health.

  • Analysts point to potential Biogen M&A options after Alzheimer's failure
    American City Business Journals25 days ago

    Analysts point to potential Biogen M&A options after Alzheimer's failure

    Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.

  • Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?
    Insider Monkey27 days ago

    Did Hedge Funds Drop The Ball On SAGE Therapeutics Inc (SAGE) ?

    A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]

  • The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage
    Zacks2 months ago

    The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

    The Zacks Analyst Blog Highlights: Celgene, Puma, Exelixis, Enanta and Sage

  • Most Analysts Have Been Positive on Sage Therapeutics in March
    Market Realist2 months ago

    Most Analysts Have Been Positive on Sage Therapeutics in March

    Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 26.25% for Sage Therapeutics (SAGE) based on the company’s

  • 5 biotech stocks that could be the next big winners
    MarketWatch2 months ago

    5 biotech stocks that could be the next big winners

    Biotech stocks are some of the most exciting investments on Wall Street. When one company develops a successful treatment for a complex condition, shares can surge overnight and attract buyout interest from Big Pharma. Case in point: Biotech giant Biogen (BIIB) imploded roughly 30% on Thursday after announcing it is canceling its Alzheimer’s drug efforts after poor drug trials.

  • 2 Biotech Takeout Targets Perfect for Biogen
    Motley Fool2 months ago

    2 Biotech Takeout Targets Perfect for Biogen

    A midsize acquisition seems imminent, and these two would fit like a glove.

  • TheStreet.com2 months ago

    A Big Outside Day and Lower Close on Sage Therapeutics Looks Bearish to Me

    , which just received FDA approval for Zulresso, the first treatment for postpartum depression. Dr. Jonas said that postpartum depression is the most common complication for women after childbirth, and suicide remains a leading cause of death among adults overall.

  • Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout
    MarketWatch2 months ago

    Shares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rollout

    Shares of Sage Therapeutics Inc. rose 3% Wednesday morning after the company’s announcement Tuesday evening that the Food and Drug Administration had approved its drug for the treatment of postpartum depression.

  • Is Sage Therapeutics a Good Stock to Buy Now?
    Motley Fool2 months ago

    Is Sage Therapeutics a Good Stock to Buy Now?

    Earning the first FDA approval for treating postpartum depression is a big step, but it's hardly an express ticket to profit town.

  • TheStreet.com2 months ago

    Fed Stops the Rate Madness: Cramer's 'Mad Money' Recap (Wednesday 3/20/19)

    Today was shaping up to be a bone-crushing session on Wall Street, Jim Cramer told his Mad Money viewers Wednesday. Without one, it will be a lot harder to own sectors like the industrials that need a strong global economy. Cramer explained that President Trump is taking a page from the Ronald Reagan playbook with Russia, "trust, but verify." The Chinese have a long history of not abiding by what they agree to, he said, which was evident most recently in the South China Sea.

  • This Biotech Stock Grabbed A First In Depression — So What's Next?
    Investor's Business Daily2 months ago

    This Biotech Stock Grabbed A First In Depression — So What's Next?

    Sage Therapeutics stock dipped Wednesday after the FDA approved its postpartum depression treatment, Zulresso. Investors are now looking at another depression drug called SAGE-217.

  • Benzinga2 months ago

    Sage's First-Of-Its-Kind Postpartum Depression Drug Clears FDA Hurdle: What You Need to Know

    Sage said the FDA approved its Zulresso — chemically brexanolone — an injection for the treatment of postpartum depression. Zulresso has both Priority Review status as well as a Breakthrough Therapy Designation from the FDA. "The potential to rapidly reduce symptoms in this critical disorder is an exciting milestone in women's mental health," said Samantha Meltzer, the primary investigator of the Zulresso clinical trials.

  • General Mills posts strong quarter, concerns at FedEx, done deal for Disney
    Yahoo Finance2 months ago

    General Mills posts strong quarter, concerns at FedEx, done deal for Disney

    General Mills, FedEx, Disney, Sage Therapeutics and Google are the companies to watch.

  • How a failed epilepsy drug became a $34,000 postpartum cure
    CNBC Videos24 days ago

    How a failed epilepsy drug became a $34,000 postpartum cure

    According to the Centers for Disease Control and Prevention, 1 in 9 women in the United States experience symptoms of postpartum depression. Looking at individual states, postpartum depression can affect as many as 1 in 5 women. In March 2019, the FDA approved the first postpartum depression drug, developed by Sage Therapeutics. Led by CEO Jeff Jonas, Sage Therapeutics created the treatment by taking a different approach toward mental health.

  • Sage Therapeutics CEO: Getting the first postpartum depre...
    CNBC Videos2 months ago

    Sage Therapeutics CEO: Getting the first postpartum depre...

    Jim Cramer talks with Sage Therapeutics CEO Jeff Jonas about the biopharma company's Zulresso drug for postpartum depression and how it could help mothers.

  • The Late Morning Rundown: March 20, 2019
    CNBC Videos2 months ago

    The Late Morning Rundown: March 20, 2019

    CNBC brings you fast, accurate, and actionable business news and market updates.

  • FDA approves postpartum depression drug created by Sage Therapeutics
    Yahoo Finance Video2 months ago

    FDA approves postpartum depression drug created by Sage Therapeutics

    The FDA approved the first-ever drug to treat postpartum depression. The drug, created by Sage Therapeutics, can be delivered as a one-time infusion into a woman’s veins over the course of 2 days. Yahoo Finance’s Alexis Christoforous shares just how much it’ll cost.